Gene therapy is part of a new wave of medicine that approaches disease treatment by addressing the root causes rather
Continue Reading Gene Therapy Approvals Gain Steam in 2023: Milestones in Second Half Pave Way for Transformative 2024
Gene Therapy Approvals Gain Steam in 2023: Treatments Offer New Hopes for Rare Diseases
After decades of intense scientific research into developing gene editing technologies, and more than a few setbacks, the field has
Continue Reading Gene Therapy Approvals Gain Steam in 2023: Treatments Offer New Hopes for Rare Diseases
Keeping Your Federally-Funded Inventions: Requirements to Comply with the Bayh-Dole Act
Federal funding is a huge boon for companies, universities, and research institutions conducting innovative research. However, it comes attached with
Continue Reading Keeping Your Federally-Funded Inventions: Requirements to Comply with the Bayh-Dole Act
The Evolving Gene Editing Landscape: From Research Tool to Market
Gene therapies have been the subject of tremendous scientific research and investment. With hundreds of clinical trials in progress and
Continue Reading The Evolving Gene Editing Landscape: From Research Tool to Market
Amgen Acquires Multispecific Immunotherapy Biotech Startup TeneoBio
On July 27, 2021, Amgen announced that it will acquire Bay area-based Teneobio, a privately held, clinical stage biotechnology
Continue Reading Amgen Acquires Multispecific Immunotherapy Biotech Startup TeneoBio
Pitfalls of Attorney-Client Privilege and Tips for Corporate Officers and Employees
Elizabeth Holmes, former CEO of the now-defunct blood-testing technology company Theranos, recently learned a harsh lesson on the complexities and
Continue Reading Pitfalls of Attorney-Client Privilege and Tips for Corporate Officers and Employees
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the
Continue Reading Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Lessons Learned From Centripetal’s Multi-Billion Dollar Damages Award Against Cisco
Centripetal Networks, Inc. (“Centripetal”), one of the fastest growing innovators in the cybersecurity space, leveraged its patent portfolio against Cisco
Continue Reading Lessons Learned From Centripetal’s Multi-Billion Dollar Damages Award Against Cisco
Is it Time to Re-evaluate (or Create) Your Document Retention Policy?
In the fast-paced and dynamic environment of startup and emerging companies, standard operating procedures and compliance matters may often fall
Continue Reading Is it Time to Re-evaluate (or Create) Your Document Retention Policy?
Atea Pharmaceuticals Collaborates with Roche on Oral COVID-19 Therapeutic
On October 22, 2020, Boston-based Atea Pharmaceuticals, Inc. (“Atea”) announced an agreement with Roche for the exclusive rights to research,
Continue Reading Atea Pharmaceuticals Collaborates with Roche on Oral COVID-19 Therapeutic